CMTM2 (CKLF-like MARVEL transmembrane domain-containing protein 2) is a member of the CMTM family, which shares structural features with both chemokines and MARVEL domain-containing proteins. It is widely expressed in human tissues, particularly in immune and reproductive systems, and plays roles in cell signaling, proliferation, and migration. Studies suggest CMTM2 is involved in immune regulation, tumorigenesis, and male reproductive system development. For example, it is highly expressed in the testes and may regulate spermatogenesis. In cancer, CMTM2 has been proposed as a tumor suppressor, with reduced expression linked to progression in malignancies like prostate and gastric cancers.
CMTM2 antibodies are essential tools for detecting and characterizing the protein’s expression, localization, and function. They are used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study CMTM2’s role in physiological and pathological contexts. Research utilizing these antibodies has highlighted CMTM2’s involvement in modulating EGFR and Wnt/β-catenin signaling pathways, potentially influencing cancer cell behavior. Additionally, CMTM2 antibodies aid in exploring its interaction with other immune-related molecules, contributing to understanding immune evasion mechanisms in tumors. These reagents are critical for both basic research and clinical investigations aiming to clarify CMTM2’s diagnostic or therapeutic potential.